{"entity":{"id":"mrna-construct-anatomy","kind":"term","name":"Messenger RNA construct anatomy","aka":["mRNA construct anatomy","mRNA untranslated regions and poly(A) tail"],"tldr":"An engineered messenger RNA includes a protein-coding message and surrounding features that affect how it is used. Those features are part of the construct being tested.","summary":"The cap, untranslated regions, coding sequence and poly(A) tail are distinct parts of a messenger RNA construct. A primary dendritic-cell study changed untranslated-region and poly(A)-tail features and measured RNA stability, protein production, peptide display and T-cell stimulation separately. Another experimental study separated effects of codon usage and RNA structure on protein expression. Construct design therefore includes more than the intended amino-acid sequence. A design that improves one measured step in one system does not establish optimal immune effects or clinical efficacy in another.\n\nStart-codon context was tested by single-base substitutions around the AUG initiator in a cloned preproinsulin gene, where the best sequence identified changed proinsulin yield over a 20-fold range (Kozak). The interaction of the cap and the poly(A) tail was tested with luciferase mRNAs delivered by electroporation into tobacco protoplasts, Chinese hamster ovary cells and yeast, where the tail's effect depended on the cap (Gallie). A textbook describes the 5' cap, 5' and 3' untranslated regions that regulate translation initiation and mRNA stability, a poly-A tail of about 200 A residues added by poly-A polymerase to cellular mRNA, and a ribosome that moves from the cap to the AUG, with Kozak's rules describing the sequence around it (OpenStax Biology 2e). The cellular tail length is not a rule for engineered constructs: one dendritic-cell study found that a 120-nucleotide tail, an unmasked tail end and two 3' untranslated regions each improved stability and translation, and it measured transcript amount by RT-PCR, protein by eGFP, peptide-MHC density and T-cell stimulation separately (Holtkamp and colleagues), so a doubled reporter signal after a 3' change is one measurement, not a different antigen or a clinical benefit. These are tested constructs and cell systems, not one best sequence for a clinical product.","asOf":"2026-11-09","links":[{"label":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.","url":"https://doi.org/10.1182/blood-2006-04-015024"},{"label":"mRNA structure regulates protein expression through changes in functional half-life.","url":"https://doi.org/10.1073/pnas.1908052116"},{"label":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.","url":"https://doi.org/10.1093/nar/gkr695"},{"label":"Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes.","url":"https://doi.org/10.1016/0092-8674(86)90762-2"},{"label":"The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency.","url":"https://doi.org/10.1101/gad.5.11.2108"},{"label":"Biology 2e, 15.4 RNA Processing in Eukaryotes (OpenStax)","url":"https://openstax.org/books/biology-2e/pages/15-4-rna-processing-in-eukaryotes"},{"label":"Biology 2e, 15.5 Ribosomes and Protein Synthesis (OpenStax)","url":"https://openstax.org/books/biology-2e/pages/15-5-ribosomes-and-protein-synthesis"}],"tags":[],"related":["codon-optimization","modified-rna-nucleosides","in-vitro-transcription","mrna-lnp-manufacturing","multi-epitope-constructs"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read a construct from its 5-prime end to its 3-prime end: cap, untranslated region, initiation context, protein-coding region, untranslated region and poly(A) tail have different jobs. A target list does not specify the finished RNA. Changing a UTR changes a regulatory sequence; changing an amino-acid spacer changes the combined protein. Sequence identity, size and integrity, end characterisation and expression need their own assays, with RNA chemistry and formulation stated."],"category":"Genomics & genetics"},"route":"/terms/mrna-construct-anatomy/","neighbours":{"term":[{"id":"codon-optimization","kind":"term","name":"Codon optimization","route":"/terms/codon-optimization/"},{"id":"delivery-target-versus-therapeutic-target","kind":"term","name":"Delivery targets and therapeutic targets","route":"/terms/delivery-target-versus-therapeutic-target/"},{"id":"immune-product-evidence","kind":"term","name":"Immune measurements and product evidence","route":"/terms/immune-product-evidence/"},{"id":"in-vitro-transcription","kind":"term","name":"In vitro transcription for RNA products","route":"/terms/in-vitro-transcription/"},{"id":"modified-rna-nucleosides","kind":"term","name":"Modified nucleosides in messenger RNA","route":"/terms/modified-rna-nucleosides/"},{"id":"multi-epitope-constructs","kind":"term","name":"Multi-epitope constructs and antigen processing","route":"/terms/multi-epitope-constructs/"}],"technology":[{"id":"mrna-lnp-manufacturing","kind":"technology","name":"mRNA and lipid nanoparticle manufacturing","route":"/technologies/mrna-lnp-manufacturing/"}]}}